Along with NRAS, Crohn’s and Colitis UK and the Psoriasis Association, NASS want to understand your experiences of switching to a biosimilar medication.
Discover the role of biosimilars in the treatment of axial SpA (AS)
The patent for adalimumab, brand name Humira® has expired. New biosimilar versions of the drug are now available.
NASS knows that not everyone in the UK gets the same standard of care for their axial SpA (AS) – that’s why we've launched our new campaign Every Patient, Every Time.
NASS works closely with the National Institute for Health and Care Excellence and Scottish Medicines Consortium, contributing to the development of the Guideline and Quality Standard for Spondyloarthritis, and offering patient perspective on drug appraisals
Spring 2016 edition of AS News magazine
Discover the role of NSAIDs in managing axial SpA (AS)
Discover the role of DMARDs in managing axial SpA (AS)
Discover the role of biologic therapy in managing axial SpA (AS)